SUNNYVALE, Calif., Sept. 12, 2019 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) strengthened its Board of Directors
with the appointment of James (Jim) M.
Hindman, effective as of September 6,
2019, and expanding the company's Board to nine members. Mr.
Hindman, an experienced healthcare executive with a 30-year tenure
at Allergan, Inc., is an accomplished financial executive with
expertise in maximizing shareholder value. He brings significant
experience in improving corporate profitability and cash flow. Mr.
Hindman will serve on the Board's Audit Committee.
Most recently, Mr. Hindman served as executive vice president,
finance and business development, and chief financial officer, at
Allergan. Through his guidance, Allergan achieved its most robust
financial performance in its 64-year history. Mr. Hindman's
previous leadership positions at Allergan include senior vice
president, treasurer, risk and investor relations, and senior vice
president, finance and controller. He currently serves on the
Boards of publicly-traded Sienna Biopharmaceuticals and Millendo
Therapeutics.
"Jim's appointment to the Board supports Accuray's continued
focus on achieving sustained financial growth," said Joshua H. Levine, President and Chief Executive
Officer of Accuray. "We have confidence we are well-positioned from
a product portfolio perspective to meet the needs of the radiation
therapy market. When combined with the establishment of our
China joint venture, we believe
these two dynamics represent a real inflection point for the
company. Jim's proven track record, financial acumen and business
expertise will be invaluable during this pivotal point in Accuray's
business."
"I am pleased to join the Accuray Board during such an exciting
time for the company," said Mr. Hindman. "The recent establishment
of the China joint venture
improves the company's long-term business prospects in China and demonstrates its commitment to
sustainable growth and expanding access to its precise radiation
therapy systems. I look forward to working with Josh, the other
Directors and senior executive team to achieve our long-term
business objectives."
About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and
sells radiotherapy systems that are intended to make cancer
treatments shorter, safer, personalized and more effective,
ultimately enabling patients to live longer, better lives. Our
radiation treatment delivery systems in combination with
fully-integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter and
YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to expectations regarding the
company's growth, the impact of the China joint venture on the company's business
prospects, ability to increase shareholder value, and ability to
meet the needs of the radiation therapy market. These
forward-looking statements involve risks and uncertainties. If any
of these risks or uncertainties materialize, or if any of the
company's assumptions prove incorrect, actual results could differ
materially from the results expressed or implied by these
forward-looking statements.
These risks and uncertainties include, but are not limited to,
the company's ability to achieve widespread market acceptance of
its products, the ability of customers in China to obtain
Class or B user licenses to purchase radiotherapy systems, the
company's ability to achieve profitability by maintaining or
increasing gross margins on its products sales and services, the
company's ability to anticipate or keep pace with changes in the
marketplace and the direction of technological innovation and
customer demands and such other risks identified under the heading
"Risk Factors" in the company's annual report on Form 10-K, filed
with the Securities and Exchange Commission (the "SEC") on
August 23, 2019, and as updated
periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Investor Contact:
Michael Polyviou
Investor Relations, EVC Group
+1 (732) 933-2755
mpolyviou@evcgroup.com
Media Contact:
Beth Kaplan
Accuray
+1 (408) 789-4426
bkaplan@accuray.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/accuray-appoints-healthcare-veteran-james-m-hindman-to-board-of-directors-300917340.html
SOURCE Accuray Incorporated